/PRQR
PRQR Stock - ProQR Therapeutics N.V.
Healthcare|BiotechnologyNASDAQ
$2.21+5.24%
+$0.11 (+5.24%) • Dec 19
78
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.53
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+64.3%upside
Target: $3.63
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PRQR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.19 – $2.23
TARGET (TP)$3.63
STOP LOSS$2.03
RISK/REWARD1:7.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.17
52W High$3.10
52W Low$1.07
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $18.91M | $6.51M | $3.59M | $1.33M | $1.03M |
| Gross Profit | $18.91M | $6.51M | $3.59M | $1.33M | $1.03M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income | $-30,472,000 | $-31,859,000 | $-65,159,000 | $-57,210,000 | $-42,368,000 |
| Net Income | $-27,763,000 | $-28,119,000 | $-64,424,000 | $-60,740,000 | $-46,565,000 |
| Net Margin | -146.9% | -431.7% | -1792.5% | -4549.8% | -4525.3% |
| EPS | $-0.34 | $-0.35 | $-0.91 | $-0.96 | $-0.93 |
Company Overview
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
Visit WebsiteRating Distribution
Strong Buy
1
17%
Buy / Outperform
5
83%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
6 Bullish0 Neutral/Bearish
Price Targets
$7
Average Target
↑ 228.1% Upside
Now
$2
Low
$7
Average
$15
High
Based on 8 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| April 29th 2025 | Cantor Fitzgerald | Resumed | Overweight | $8 |
| April 29th 2025 | Evercore ISI | Initiation | Outperform | $5 |
| March 10th 2025 | Citigroup | Upgrade | Buy | $4 |
| January 10th 2025 | Oppenheimer | Initiation | Outperform | $15 |
| October 29th 2024 | Raymond James | Upgrade | Strong Buy | $14← $6 |
| November 8th 2023 | Chardan Capital Markets | Upgrade | Buy | $2 |
| March 30th 2023 | JMP Securities | Upgrade | Mkt Outperform | $5← $1.5 |
| December 22nd 2022 | Cantor Fitzgerald | Upgrade | Overweight | $5← $0.8 |
Earnings History & Surprises
PRQRBeat Rate
39%
Last 18 quarters
Avg Surprise
-4.6%
EPS vs Estimate
Beats / Misses
7/8
3 met exactly
Latest EPS
$-0.12
Q4 2025
EPS Surprise History
Q1 24
0.0%
$-0.08vs$-0.08
Q2 24
+16.7%
$-0.10vs$-0.12
Q3 24
+75.0%
$-0.03vs$-0.12
Q4 24
+8.3%
$-0.11vs$-0.12
Q1 25
0.0%
$-0.10vs$-0.10
Q2 25
-22.2%
$-0.11vs$-0.09
Q3 25
-75.0%
$-0.14vs$-0.08
Q4 25
-20.0%
$-0.12vs$-0.10
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Mar 12, 2026 | $-0.08 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.10 | $-0.12 | -20.0% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $-0.08 | $-0.14 | -75.0% | ✗ MISS |
Q2 2025 | May 8, 2025 | $-0.09 | $-0.11 | -22.2% | ✗ MISS |
Q1 2025 | Mar 13, 2025 | $-0.10 | $-0.10 | 0.0% | = MET |
Q4 2024 | Nov 7, 2024 | $-0.12 | $-0.11 | +8.3% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.12 | $-0.03 | +75.0% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.12 | $-0.10 | +16.7% | ✓ BEAT |
Q1 2024 | Mar 13, 2024 | $-0.08 | $-0.08 | 0.0% | = MET |
Q4 2023 | Nov 7, 2023 | $-0.06 | $-0.08 | -33.3% | ✗ MISS |
Q3 2023 | Aug 3, 2023 | $-0.12 | $-0.11 | +8.3% | ✓ BEAT |
Q2 2023 | May 16, 2023 | $-0.12 | $-0.12 | 0.0% | = MET |
Q1 2023 | Mar 29, 2023 | $-0.20 | $-0.16 | +20.0% | ✓ BEAT |
Q4 2022 | Nov 9, 2022 | $-0.23 | $-0.34 | -47.8% | ✗ MISS |
Q3 2022 | Aug 4, 2022 | $-0.26 | $-0.22 | +15.4% | ✓ BEAT |
Q2 2022 | May 5, 2022 | $-0.25 | $-0.22 | +12.0% | ✓ BEAT |
Q1 2022 | Feb 24, 2022 | $-0.26 | $-0.30 | -15.4% | ✗ MISS |
Q4 2021 | Nov 4, 2021 | $-0.23 | $-0.26 | -13.0% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $-0.26 | $-0.29 | -11.5% | ✗ MISS |
Latest News
ProQR Therapeutics Q3 EPS $(0.10), Inline, Sales $2.882M Miss $8.550M Estimate
📉 NegativeBenzinga•Nov 6, 2025, 12:16 PM
Chardan Capital Maintains Buy on ProQR Therapeutics, Maintains $4 Price Target
📈 PositiveBenzinga•Nov 4, 2025, 01:26 PM
ProQR Therapeutics Gets European Medicines Agency's Committee's Authorization For Clinical Trial Application For Phase 1 Trial Of AX-0810 To Treat Clerosing Cholangitis, Biliary Atresia
📈 PositiveBenzinga•Oct 20, 2025, 12:12 PM
ProQR Announces Central Committee On Research Involving Human Subjects Has Authorized Co.'s Clinical Trial Application For Phase 1 Study Of AX-0810
📈 PositiveBenzinga•Oct 20, 2025, 12:07 PM
Frequently Asked Questions about PRQR
What is PRQR's current stock price?
ProQR Therapeutics N.V. (PRQR) is currently trading at $2.21 per share. The stock has moved +5.24% today.
What is the analyst price target for PRQR?
The average analyst price target for PRQR is $3.63, based on 1 analyst.
What sector is ProQR Therapeutics N.V. in?
ProQR Therapeutics N.V. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is PRQR's market cap?
ProQR Therapeutics N.V. has a market capitalization of $0.23 billion, making it a small-cap company.
Does PRQR pay dividends?
No, ProQR Therapeutics N.V. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACHV
Achieve Life Sciences, Inc.
$4.32
Mkt Cap: $0.2B
ALLO
Allogene Therapeutics, Inc.
$1.42
Mkt Cap: $0.3B
ARCT
Arcturus Therapeutics Holdings Inc.
$6.53
Mkt Cap: $0.2B
CAPR
Capricor Therapeutics, Inc.
$27.81
Mkt Cap: $1.3B
EDIT
Editas Medicine, Inc.
$2.34
Mkt Cap: $0.2B
IMMP
Immutep Limited
$2.63
Mkt Cap: $0.4B
MREO
Mereo BioPharma Group plc
$2.00
Mkt Cap: $0.3B
TRDA
Entrada Therapeutics, Inc.
$10.98
Mkt Cap: $0.4B
VNDA
Vanda Pharmaceuticals Inc.
$6.75
Mkt Cap: $0.4B
ZURA
Zura Bio Limited
$4.27
Mkt Cap: $0.3B
Explore stocks similar to PRQR for comparison